Hedgehog Pathway Inhibition

Area of Science:

• Oncology
• Molecular Biology
• Dermatology

Background:

• Aberrant activation of the hedgehog (Hh) signaling pathway is a hallmark of basal cell carcinoma (BCC).
• This pathway plays a critical role in the development and progression of BCC.
• Understanding Hh pathway dysregulation is key to developing effective treatments.

Purpose of the Study:

• To review the role of the hedgehog (Hh) signaling pathway in basal cell carcinoma (BCC).
• To discuss the mechanism of action of Smoothened (SMO) inhibitors.
• To highlight the clinical applications of approved SMO inhibitors in BCC treatment.

Main Methods:

• Literature review of studies on hedgehog signaling in BCC.
• Analysis of clinical trial data for SMO inhibitors.
• Review of regulatory approvals for BCC therapies.

Main Results:

• The hedgehog (Hh) signaling pathway is frequently hyperactivated in basal cell carcinomas (BCC).
• Vismodegib and sonidegib are targeted therapies that inhibit Smoothened (SMO), a key component of the Hh pathway.
• Both vismodegib and sonidegib are approved for treating locally advanced BCC (laBCC).

Conclusions:

• Targeted inhibition of the Smoothened (SMO) component of the hedgehog (Hh) pathway is an effective strategy for basal cell carcinoma (BCC) treatment.
• Vismodegib and sonidegib represent significant advancements in managing locally advanced and metastatic BCC.
• Continued research into Hh pathway inhibitors may offer further therapeutic options for BCC patients.